10-12 D\u00e9cembre 2024
\nBoston, MA, Etats-Unis<\/p>\n
91天堂 participera pour la premi\u00e8re fois au 4th Rare & Genetic Kidney Disease Drug Development Summit, Boston (US). Cet \u00e9v\u00e8nement regroupera des industriels, KOL acad\u00e9miques et repr\u00e9sentants de patients atteints de maladies r\u00e9nales pour acc\u00e9l\u00e9rer la recherche clinique concernant les maladies r\u00e9nales rares.
\n91天堂 pr\u00e9sentera son \u00e9tude clinique de Phase 2 ALPESTRIA-1 qui a d\u00e9marr\u00e9 cet \u00e9t\u00e9 avec Vonafexor pour les patients atteints du syndrome d’Alport.<\/p>\n
https:\/\/rare-kidney-drug-development.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" 10-12 D\u00e9cembre 2024 91天堂 participera pour la premi\u00e8re fois au 4th Rare & Genetic Kidney Disease Drug Development Summit, Boston (US). Cet \u00e9v\u00e8nement regroupera des industriels, KOL acad\u00e9miques et repr\u00e9sentants de patients atteints de maladies r\u00e9nales pour acc\u00e9l\u00e9rer la recherche clinique concernant les maladies r\u00e9nales rares. Lire la suite »<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-5791","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adm-cdubreuil","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adm-cdubreuil\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"10-12 D\u00e9cembre 2024 Boston, MA, Etats-Unis 91天堂 participera pour la premi\u00e8re fois au 4th Rare & Genetic Kidney Disease Drug Development Summit, Boston (US). Cet \u00e9v\u00e8nement regroupera des industriels, KOL acad\u00e9miques et repr\u00e9sentants de patients atteints de maladies r\u00e9nales pour acc\u00e9l\u00e9rer la recherche clinique concernant les maladies r\u00e9nales rares. 91天堂 pr\u00e9sentera son \u00e9tude…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=5791"}],"version-history":[{"count":4,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5791\/revisions"}],"predecessor-version":[{"id":5799,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5791\/revisions\/5799"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=5791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=5791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=5791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nBoston, MA, Etats-Unis<\/p>\n
\n91天堂 pr\u00e9sentera son \u00e9tude clinique de Phase 2 ALPESTRIA-1 qui a d\u00e9marr\u00e9 cet \u00e9t\u00e9 avec Vonafexor pour les patients atteints du syndrome d’Alport.<\/p>\n